img

Global Myasthenia Gravis Drugs Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 320 | Industry : Pharma & Healthcare

Publisher : GRD Survey | Format : PDF

Global Myasthenia Gravis Drugs Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global Myasthenia Gravis Drugs market is estimated at million US$ in 2021 and is expected to reach million US$ by the end of 2028, growing at a CAGR of % in the forecast period between 2022 and 2028.

This report studies the Myasthenia Gravis Drugs market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Myasthenia Gravis Drugs in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins

Market Snapshot, By Application
Hospitals
Clinics

Main Market Players Analyzed in this report, including
Takeda
Pfizer
Novartis
Mitsubishi Tanabe Pharma
Lupin Pharmaceuticals
Grifols
GlaxoSmithKline
Galencia
Flamel Technologies
F. Hoffmann-La Roche
Cytokinetics
Curavac
CSL
Catalyst Pharmaceuticals
Bausch Health
Alexion Pharmaceuticals

The study objectives of this report are
To study and analyze the global Myasthenia Gravis Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Myasthenia Gravis Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Myasthenia Gravis Drugs manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Myasthenia Gravis Drugs market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Myasthenia Gravis Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Myasthenia Gravis Drugs are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Myasthenia Gravis Drugs Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Myasthenia Gravis Drugs Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Myasthenia Gravis Drugs

3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Myasthenia Gravis Drugs Sales Channel and Distributors Analysis
3.3.1 Myasthenia Gravis Drugs Sales Channel
3.3.2 Myasthenia Gravis Drugs Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Hospitals
3.4.2 Major Buyers in Clinics
3.5 Myasthenia Gravis Drugs Manufacturing Cost Structure Analysis

4 Market Segment: by Type
4.1 Myasthenia Gravis Drugs Type Introduction
4.1.1 Anticholinesterases
4.1.2 Immunosuppressants
4.1.3 Intravenous Immune Globulins
4.2 Global Myasthenia Gravis Drugs Sales by Type 2016-2021
4.3 Global Myasthenia Gravis Drugs Revenue by Type 2016-2021
4.4 Global Myasthenia Gravis Drugs Price by Type 2016-2021

5 Market Segment: by Application
5.1 Myasthenia Gravis Drugs Type Introduction
5.1.1 Hospitals
5.1.2 Clinics
5.2 Global Myasthenia Gravis Drugs Sales by Application 2016-2021
5.3 Global Myasthenia Gravis Drugs Revenue by Application 2016-2021
5.4 Global Myasthenia Gravis Drugs Price by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Myasthenia Gravis Drugs Market by Region
6.1.1 Global Myasthenia Gravis Drugs Sales by Regions
6.1.2 Global Myasthenia Gravis Drugs Revenue by Regions
6.2 North America Myasthenia Gravis Drugs Market 2016-2021
6.3 Europe Myasthenia Gravis Drugs Market 2016-2021
6.4 Asia Pacific Myasthenia Gravis Drugs Market 2016-2021
6.5 South America Myasthenia Gravis Drugs Market 2016-2021
6.6 Middle East and Africa Myasthenia Gravis Drugs Market 2016-2021

7 North America
7.1 North America Myasthenia Gravis Drugs Market by Country 2016-2021
7.1.1 North America Myasthenia Gravis Drugs Sales by Country
7.1.2 North America Myasthenia Gravis Drugs Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Myasthenia Gravis Drugs Market by Country 2016-2021
8.1.1 Europe Myasthenia Gravis Drugs Sales by Country
8.1.2 Europe Myasthenia Gravis Drugs Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Myasthenia Gravis Drugs Market by Country 2016-2021
9.1.1 Asia Pacific Myasthenia Gravis Drugs Sales by Country
9.1.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Myasthenia Gravis Drugs Market by Country 2016-2021
10.1.1 South America Myasthenia Gravis Drugs Sales by Country
10.1.2 South America Myasthenia Gravis Drugs Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Myasthenia Gravis Drugs Market by Country 2016-2021
11.1.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Country
11.1.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Takeda
12.1.1 Takeda Company Information
12.1.2 Takeda Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.1.3 Takeda Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Takeda Key Development
12.2 Pfizer
12.2.1 Pfizer Company Information
12.2.2 Pfizer Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.2.3 Pfizer Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Pfizer Key Development
12.3 Novartis
12.3.1 Novartis Company Information
12.3.2 Novartis Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.3.3 Novartis Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 Novartis Key Development
12.4 Mitsubishi Tanabe Pharma
12.4.1 Mitsubishi Tanabe Pharma Company Information
12.4.2 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.4.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Mitsubishi Tanabe Pharma Key Development
12.5 Lupin Pharmaceuticals
12.5.1 Lupin Pharmaceuticals Company Information
12.5.2 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.5.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Lupin Pharmaceuticals Key Development
12.6 Grifols
12.6.1 Grifols Company Information
12.6.2 Grifols Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.6.3 Grifols Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 Grifols Key Development
12.7 GlaxoSmithKline
12.7.1 GlaxoSmithKline Company Information
12.7.2 GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.7.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 Grifols Key Development
12.9 Flamel Technologies
12.9.1 Flamel Technologies Company Information
12.9.2 Flamel Technologies Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.9.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Flamel Technologies Key Development
12.8 Galencia
12.8.1 Galencia Company Information
12.8.2 Galencia Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.8.3 Galencia Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Galencia Key Development
12.11 Cytokinetics
12.11.1 Cytokinetics Company Information
12.11.2 Cytokinetics Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.11.3 Cytokinetics Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.11.4 Cytokinetics Key Development
12.12 Curavac
12.12.1 Curavac Company Information
12.12.2 Curavac Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.12.3 Curavac Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.12.4 Curavac Key Development
12.13 CSL
12.13.1 CSL Company Information
12.13.2 CSL Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.13.3 CSL Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.13.4 CSL Key Development
12.14 Catalyst Pharmaceuticals
12.14.1 Catalyst Pharmaceuticals Company Information
12.14.2 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.14.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.14.4 Catalyst Pharmaceuticals Key Development
12.15 Bausch Health
12.15.1 Bausch Health Company Information
12.15.2 Bausch Health Myasthenia Gravis Drugs Product Portfolio, Specification and Application
12.15.3 Bausch Health Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
12.15.4 Bausch Health Key Development

13 Global Myasthenia Gravis Drugs Market Forecast by Region by Type and by Application
13.1 Global Myasthenia Gravis Drugs Sales, Revenue Forecast 2022-2027
13.2 Global Myasthenia Gravis Drugs Forecast by Regions
13.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Region 2022-2027
13.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Region 2022-2027
13.3 Global Myasthenia Gravis Drugs Forecast by Type
13.3.1 Global Myasthenia Gravis Drugs Sales Forecast by Type 2022-2027
13.3.2 Global Myasthenia Gravis Drugs Revenue Forecast by Type 2022-2027
13.3.3 Global Myasthenia Gravis Drugs Price Forecast by Type 2022-2027
13.4 Global Myasthenia Gravis Drugs Forecast by Application
13.4.1 Global Myasthenia Gravis Drugs Sales Forecast by Application 2022-2027
13.4.2 Global Myasthenia Gravis Drugs Revenue Forecast by Application 2022-2027
13.4.3 Global Myasthenia Gravis Drugs Price Forecast by Application 2022-2027

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer

List of Figure

List of Tables

Table 1: Global Myasthenia Gravis Drugs Production Specifications
Table 2: Drivers in Myasthenia Gravis Drugs Market
Table 3: Restraints Myasthenia Gravis Drugs Market
Table 4: Opportunity in Myasthenia Gravis Drugs Market
Table 5: Comparion of Alternative and Myasthenia Gravis Drugs
Table 6: Myasthenia Gravis Drugs Raw Materials Key Suppliers List
Table 7: Myasthenia Gravis Drugs Distributors List
Table 8: Myasthenia Gravis Drugs Major Buyers in Hospitals
Table 9: Myasthenia Gravis Drugs Major Buyers in Clinics
Table 10: Myasthenia Gravis Drugs Major Buyers in
Table 11: Global Myasthenia Gravis Drugs Sales (K Units) by Type 2016-2021
Table 12: Global Myasthenia Gravis Drugs Sales Market Share by Type 2016-2021
Table 13: Global Myasthenia Gravis Drugs Revenue (Million USD) by Type 2016-2021
Table 14: Global Myasthenia Gravis Drugs Revenue Market Share by Type 2016-2021
Table 15: Global Myasthenia Gravis Drugs Price by Type 2016-2021
Table 16: Global Myasthenia Gravis Drugs Sales (K Units) by Application 2016-2021
Table 17: Global Myasthenia Gravis Drugs Sales Market Share by Application 2016-2021
Table 18: Global Myasthenia Gravis Drugs Revenue (Million USD) by Application 2016-2021
Table 19: Global Myasthenia Gravis Drugs Revenue Market Share by Application 2016-2021
Table 20: Global Myasthenia Gravis Drugs Price by Application 2016-2021
Table 21: Global Myasthenia Gravis Drugs Sales (K Units) by Region 2016-2021
Table 22: Global Myasthenia Gravis Drugs Sales Market Share by Region 2016-2021
Table 23: Global Myasthenia Gravis Drugs Revenue (Million USD) by Region 2016-2021
Table 24: Global Myasthenia Gravis Drugs Revenue Market Share by Region 2016-2021
Table 25: North America Myasthenia Gravis Drugs Sales (K Units) by Country 2016-2021
Table 26: North America Myasthenia Gravis Drugs Sales Market Share by Country 2016-2021
Table 27: North America Myasthenia Gravis Drugs Revenue (Million USD) by Country 2016-2021
Table 28: North America Myasthenia Gravis Drugs Revenue Market Share by Country 2016-2021)
Table 29: Europe Myasthenia Gravis Drugs Sales (K Units) by Country 2016-2021
Table 30: Europe Myasthenia Gravis Drugs Sales Market Share by Country 2016-2021
Table 31: Europe Myasthenia Gravis Drugs Revenue (Million USD) by Country 2016-2021
Table 32: Europe Myasthenia Gravis Drugs Revenue Market Share by Country 2016-2021)
Table 33: Asia Pacific Myasthenia Gravis Drugs Sales (K Units) by Country 2016-2021
Table 34: Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Country 2016-2021
Table 35: Asia Pacific Myasthenia Gravis Drugs Revenue (Million USD) by Country 2016-2021
Table 36: Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Country 2016-2021)
Table 37: South America Myasthenia Gravis Drugs Sales (K Units) by Country 2016-2021
Table 38: South America Myasthenia Gravis Drugs Sales Market Share by Country 2016-2021
Table 39: South America Myasthenia Gravis Drugs Revenue (Million USD) by Country 2016-2021
Table 40: South America Myasthenia Gravis Drugs Revenue Market Share by Country 2016-2021)
Table 41: Middle East and Africa Myasthenia Gravis Drugs Sales (K Units) by Country 2016-2021
Table 42: Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Country 2016-2021
Table 43: Middle East and Africa Myasthenia Gravis Drugs Revenue (Million USD) by Country 2016-2021
Table 44: Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Country 2016-2021)
Table 45 Takeda Company Information
Table 46 Takeda Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 47 Takeda Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 48 Pfizer Company Information
Table 49 Pfizer Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 50 Pfizer Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 51 Novartis Company Information
Table 52 Novartis Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 53 Novartis Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 54 Mitsubishi Tanabe Pharma Company Information
Table 55 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 56 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 57 Lupin Pharmaceuticals Company Information
Table 58 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 59 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 60 Grifols Company Information
Table 61 Grifols Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 62 Grifols Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 63 GlaxoSmithKline Company Information
Table 64 GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 65 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 66 Galencia Company Information
Table 67 Galencia Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 68 Galencia Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 69 Flamel Technologies Company Information
Table 70 Flamel Technologies Myasthenia Gravis Drugs Product Portfolio, Specification and Application
Table 71 Flamel Technologies Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
Table 72: Global Myasthenia Gravis Drugs Sales (K Units) Forecast by Region (2022-2027)
Table 73: Global Myasthenia Gravis Drugs Sales Market Share Forecast by Region (2012-2027)
Table 74: Global Myasthenia Gravis Drugs Revenue (Million USD) Forecast by Region (2022-2027)
Table 75: Global Myasthenia Gravis Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 76: Global Myasthenia Gravis Drugs Sales (K Units) Forecast by Type (2022-2027)
Table 77: Global Myasthenia Gravis Drugs Sales Market Share Forecast by Type (2012-2027)
Table 78: Global Myasthenia Gravis Drugs Revenue (Million USD) Forecast by Type (2022-2027)
Table 79: Global Myasthenia Gravis Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 80: Global Myasthenia Gravis Drugs Sales (K Units) Forecast by Applicaion (2022-2027)
Table 81: Global Myasthenia Gravis Drugs Sales Market Share Forecast by Application (2012-2027)
Table 82: Global Myasthenia Gravis Drugs Revenue (Million USD) Forecast by Application (2022-2027)
Table 83: Global Myasthenia Gravis Drugs Revenue Market Share Forecast by Application (2022-2027)


List of Figures

Figure 1: Myasthenia Gravis Drugs Picture
Figure 2: Global Myasthenia Gravis Drugs Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Myasthenia Gravis Drugs Supply Chain Analysis
Figure 5: Myasthenia Gravis Drugs Manufacturing Cost Structure Analysis
Figure 6: Product Picture of Anticholinesterases
Figure 7: Product Picture of Immunosuppressants
Figure 8: Global Myasthenia Gravis Drugs Sales Market Share by Type, 2020
Figure 9: Global Myasthenia Gravis Drugs Revenue Market Share by Type, 2020
Figure 10: Myasthenia Gravis Drugs in Hospitals
Figure 11: Global Myasthenia Gravis Drugs Market: Hospitals 2016-2021
Figure 12: Myasthenia Gravis Drugs in Clinics
Figure 13: Global Myasthenia Gravis Drugs Market: Clinics 2016-2021
Figure 14: Global Myasthenia Gravis Drugs Sales Market Share by Application, 2020
Figure 15: Global Myasthenia Gravis Drugs Revenue Market Share by Application, 2020
Figure 16: Global Myasthenia Gravis Drugs Sales Market Share by Region 2016-2021
Figure 17: Global Myasthenia Gravis Drugs Revenue Market Share by Region 2016-2021
Figure 18: North America Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 19: North America Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 20: Europe Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 21: Europe Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 23: Asia Pacific Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 24: South America Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 25: South America Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 26: Middle East and Africa Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 27: Middle East and Africa Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 28: North America Myasthenia Gravis Drugs Sales Market Share by Country, 2020
Figure 29: North America Myasthenia Gravis Drugs Revenue Market Share by Country, 2020
Figure 30: United States Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 31: United States Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 32: Canada Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 33: Canada Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 34: Mexico Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 35: Mexico Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 36: Europe Myasthenia Gravis Drugs Sales Market Share by Country, 2020
Figure 37: Europe Myasthenia Gravis Drugs Revenue Market Share by Country, 2020
Figure 38: Germany Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 39: Germany Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 40: France Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 41: France Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 42: UK Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 43: UK Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 44: Italy Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 45: Italy Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 46: Russia Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 46: Russia Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 47: Spain Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 48: Spain Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 49: Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Country, 2020
Figure 50: Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Country, 2020
Figure 51: China Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 52: China Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 53: Japan Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 54: Japan Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 55: Korea Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 56: Korea Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 57: Southeast Asia Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 58: Southeast Asia Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 59: India Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 60: India Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 61: Australia Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 62: Australia Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 63: South America Myasthenia Gravis Drugs Sales Market Share by Country, 2020
Figure 64: South America Myasthenia Gravis Drugs Revenue Market Share by Country, 2020
Figure 65: Brazil Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 66: Brazil Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 67: Argentina Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 68: Argentina Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 69: Colombia Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 70: Colombia Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 71: Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Country, 2020
Figure 72: Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Country, 2020
Figure 73: Turkey Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 74: Turkey Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 75: Saudi Arabia Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 76: Saudi Arabia Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 77: South Africa Myasthenia Gravis Drugs Sales (K Units) Status 2016-2021
Figure 78: South Africa Myasthenia Gravis Drugs Revenue (Million USD) Status 2016-2021
Figure 79: Takeda Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 80: Pfizer Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 81: Novartis Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 82: Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 83: Lupin Pharmaceuticals Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 84: Grifols Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 85: GlaxoSmithKline Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 86: Galencia Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 87: Flamel Technologies Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 88: F. Hoffmann-La Roche Myasthenia Gravis Drugs Revenue Market Share Globally (2019-2021)
Figure 89: Global Myasthenia Gravis Drugs Sales (K Units) Forecast (2022-2027)
Figure 90: Global Myasthenia Gravis Drugs Sales (K Units) Forecast (2022-2027)